Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The glucocorticoid receptor ligand-binding domain (GR-LBD) is a critical component of the glucocorticoid receptor, a member of the nuclear receptor superfamily. Upon binding to glucocorticoid ligands, the GR undergoes conformational changes that facilitate its translocation into the nucleus and interaction with specific DNA sequences called glucocorticoid response elements (GREs). This interaction modulates the expression of genes involved in inflammation, metabolism, and immune response. The GR-LBD is crucial for the regulation of these biological processes and serves as a target for therapeutic interventions in conditions such as inflammatory diseases and metabolic disorders.
Modulation of gene expression via transcription activation or repression after ligand binding; interaction with coactivators or corepressors like PGC1α.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glucocorticoid receptor ligand-binding domain (GR-LBD).